Connected Kansas Kids

Skip Navigation LinksHome » Diagnoses » Systemic Lupus Erythematosis » SLE (Lupus), Part 1 — Introduction, incidence, and symptoms
Connected Kansas Kids -- The place for special kids and their parents.

Lupus, Part 1 — Introduction, incidence, and symptoms

What is systemic lupus erythematosus?

Systemic lupus erythematosus (SLE) (lupus) is an episodic multi system disease characterized by widespread inflammation of the blood vessels and connective tissues. Lupus is a chronic disease but the symptoms may come and go after the initial diagnosis. Lupus can be unpredictable and dangerous and require regular care from doctors who are skilled in treating children. We do not know what causes lupus but sun exposure can trigger lupus in individuals prone to getting lupus. More females than males get lupus and female hormones which reach high levels during puberty may allow lupus to occur more easily. Certain medications can also cause an illness similar to lupus that usually goes away when the mediations are stopped.

Incidence and prevalence

Incidence of this disease varies by location and ethnicity. Incidence rates among children younger than 15 years have been reported to be between 0.5 and 0.6 per 100,000 persons. Prevalence rates of 4-250 per 100,000 persons have been measured, with greater prevalence in Native American, Asian, Latin American, and black patients. In one study of adults, the incidence in African American females was estimated at 1 in 500. The 5-year survival rate for children with SLE is more than 90%. Most deaths of children with SLE are the result of infection, nephritis, renal failure, CNS disease, or pulmonary hemorrhage. Myocardial infarction may occur in the young adult years as a complication of long-term corticosteroid use. Prevalence rates are higher in Native American, Asian, Latin American, and black patients. Prevalence rates are higher in females than in males. A female-to-male ratio of approximately 2:1 occurs before puberty, and a ratio of 4:1 occurs after puberty. Approximately 20% of patients with SLE initially present by the second decade of life. Disease onset has been reported as early as the first year of life. However, SLE remains uncommon in children younger than 8 years.

Symptoms

Presenting symptoms: The most frequent presenting symptoms of SLE are prolonged fever and malaise with evidence of multisystem involvement. The children often present with a history of fatigue, joint pain, rash, and fever. However, children may present with a variety of acute symptoms, including memory loss, psychosis, transverse myelitis, hemoptysis, edema of the lower extremities, headache, and painful mouth sores. Many children develop a rash on their face or chest, particularly after being in the sun. Eleven criteria are used for the classification of lupus in adults. The same criteria can serve as a guideline in children. Any 4 criteria are sufficient and should be sought in the history. Of note, ANA is almost always present. Diagnosis is not difficult in the child who presents with many manifestations, such as malar rash, pleuritic chest pain, nephritis, and a positive ANA. Some patients present over longer periods and require careful consideration. Occasionally, a definite diagnosis never develops or the patient may have an overlap syndrome with manifestations of several rheumatic diseases. Joints may become swollen and stiff. Mouth ulcers may come and go. Sometimes more hair falls out than the normal amount. The hands may turn red, white and blue when exposed to cold such as gripping a cold drink or going into air conditioning or outside in the cold. Children may also present with internal organ involvement in the kidneys, brain, heart, or lungs. Lupus is more serious if involvement is in the internal organs.

Ongoing symptoms: Children with inflammation of the kidneys develop nephritis; those with brain involvement may have seizures, serious mood changes or hallucinations; others may have fluid around the heart or lungs.


Lupus, Part 1 — Introduction, incidence, and symptoms

Lupus, Part 2 — Treatment, side-effects, restrictions, and implications for school

 


For more information, please contact:

Kathy Davis, MSEd, PhD
kdavis2@kumc.edu
(913) 588-6305